Amylyx(US:AMLX) Yahoo Finance·2025-10-26 10:16Core Viewpoint - Amylyx Pharmaceuticals Inc. is recognized as a small-cap stock with significant upside potential, particularly following a price target increase by Bank of America Securities from $14 to $16 while maintaining a 'Buy' rating [1][2]. Financial Performance - The price target increase is attributed to Amylyx raising $175 million through the issuance of 17.5 million shares, with net proceeds amounting to $163 million, which extends the company's cash runway beyond 2027 [2][3]. Strategic Initiatives - The strengthened balance sheet allows the company to invest in commercial ramp-up activities, including pivotal Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia, expected in the first half of 2026 [3]. - Additionally, Amylyx is on track to deliver cohort data from the AMX0114 program in ALS by the end of the year [3]. Company Overview - Amylyx Pharmaceuticals Inc. focuses on discovering and developing novel treatments for neurodegenerative diseases and other serious conditions with high unmet medical needs, including amyotrophic lateral sclerosis (ALS) [4].